Academic Journal of Second Military Medical University (第二军医大学学报) 2015/36:12 PP.1319-1323
Objective To evaluate the preventive effect of pancreatic duct stent against post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) and hyperamylasemia in high-risk patients. Methods A total of 160 patients with high-risk PEP underwent ERCP therapy between Jan. 2013 and Dec. 2014 and were retrospectively analyzed. The patients were divided into pancreatic duct stent group (n=82) and control group (n=78) according to whether receiving pancreatic duct stent or not. Abdominal pain was evaluated after ERCP. The levels of serum amylase were detected at 3 h and 24 h after ERCP. The incidences of PEP and hyperamylasemia were compared between the two groups. Results The serum amylase levels at 3 h and 24 h after ERCP in pancreatic duct stent group were significantly lower than those in control group ([184.89±257.33] U/L vs [305.35±371.81] U/L, P <0.05; [268.07±344.73] U/L vs [465.86±639.94] U/L, P <0.05). The incidences of PEP and hyperamylasemia in pancreatic duct stent group were also significantly lower than those in control group (2.4%[2/82] vs 11.5%[9/78], P <0.05;17.1%[14/82] vs 30.8%[24/78], P <0.05). The incidence of abdominal pain and abdominal pain score were (19.5%[16/82], [1.24±0.58]) in pancreatic duct stent group, which were significantly lower than those in control group (43.6% [34/78], [1.68±0.97]) ( P =0.001). Conclusion Pancreatic duct stent can effectively prevent PEP and hyperamylasemia in high-risk patients following ERCP.
 Kawaguchi Y, Ogawa M, Omata F, Ito H, Shimosegawa T, Mine T. Randomized controlled trial of pancreatic stenting to prevent pancreatitis after endoscopic retrograde cholangiopancreatography[J]. World J Gastroenterol, 2012, 18:1635-1641.
 Shi Q Q, Ning X Y, Zhan L L. Placement of prophylactic pancreatic stents to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a meta-analysis[J]. World J Gastroenterol, 2014, 20: 7040-7048.
 中华医学会消化内镜分会ERCP学组.ERCP诊治指南[J].中华消化内镜杂志, 2010, 27:113-118.
 Dumonceau J M, Andriulli A, Elmunzer B J, Mariani A, Meister T, Deviere J, et al. Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline-Updated June 2014[J]. Endoscopy, 2014, 46:799-815.
 Cotton P B, Lehman G, Vennes J, Geenen J E, Russell R C, Meyers W C, et al.Endoscopic sphincterotomy complications and their management:an attempt at consensus[J].Gastrointest Endosc, 1991, 37:383-393.
 刘 璐, 邓 涛, 万新月, 覃 念.胰管支架预防高危ERCP术后胰腺炎的临床分析[J].胃肠病学和肝病学杂志, 2013, 22:1087-1090.
 Katsinelos P, Lazaraki G, Chatzimavroudis G, Gkaqkalis S, Vasiliadis I, Papaeuthimiou A, et al. Risk factors for therapeutic ERCP-related complications: an analysis of 2, 715 cases performed by a single endoscopist[J]. Ann Gastroenterol, 2014, 27:65-72.
 Elmunzer B J, Scheiman J M, Lehman G A, Chak A, Mosler P, Higgins P D, et al. A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis[J]. N Engl J Med, 2012, 366:1414-1422.
 Iorgulescu A, Sandu I, Turcu F, Iordache N. Post-ERCP acute pancreatitis and its risk factors[J]. J Med Life, 2013, 6:109-113.
 Tarnasky P R. Mechanical prevention of post-ERCP pancreatitis by pancreatic stents:results, techniques, and indications [J]. JOP, 2003, 4:58-67.
 王苏丽, 周 毅, 谢 艳, 林 涛, 王 钧, 姚 茹.胰管支架置入术预防逆行胰胆管造影术后胰腺炎高危患者PEP及高淀粉酶血症研究[J].中国中西医结合消化杂志, 2013, 21:146-149.
 秦向荣, 薛乐宁, 王 强, 范志宁, 王 翔.胰管支架预防困难ERCP术后胰腺炎及高淀粉酶血症的疗效观察[J].中华消化内镜杂志, 2010, 27:210-211.
 Sofuni A, Maguchi H, Mukai T, Kawakami H, Irisawa A, Kubota K, et al. Endoscopic pancreatic duct stents reduce the incidence of post-endoscopic retrograde cholangio- pancreatography pancreatitis in high-risk patients[J]. Clin Gastreenterol Hepatol, 2011, 9: 851-858.
 Chen J J, Wang X M, Liu X Q. Risk factors for post-ERCP pancreatitis: a systematic review of clinical trials with a large sample size in the past 10 years[J]. Eur J Med Res, 2014, 5:19-26.
 李运红, 姚玉玲, 贺奇彬, 曹 俊, 吴 寒, 吴毓麟, 等.胰管支架预防困难胆管插管ERCP术后急性胰腺炎的前瞻性研究[J].中华消化内镜杂志, 2014, 31:403-406.